Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Tharimmune (NASDAQ:THAR) has appointed renowned philanthropist Nancy Davis to its Board of Directors. Davis, founder of Race to Erase MS and Cure Addiction Now (CAN), brings extensive experience in patient advocacy and medical research advancement. Her organization Race to Erase MS has raised over $56 million for MS research through its "Center Without Walls" program, contributing to the development of FDA-approved therapies like Ocrevus®, Briumvi®, and Kesimpta®.
Davis's appointment is particularly significant as Tharimmune advances TH104, their investigational product being developed as a countermeasure against weaponized fentanyl for military use and chemical incident responders, with potential applications in addressing the opioid crisis. Her experience with CAN, which focuses on innovative addiction treatment research, aligns with Tharimmune's mission to develop breakthrough therapies for inflammation, immunology, and critical unmet medical needs.
Tharimmune (NASDAQ:THAR) ha nominato la rinomata filantropa Nancy Davis nel suo Consiglio di Amministrazione. Davis, fondatrice di Race to Erase MS e Cure Addiction Now (CAN), porta con sé una vasta esperienza nel campo della difesa dei pazienti e dell'avanzamento della ricerca medica. La sua organizzazione Race to Erase MS ha raccolto oltre 56 milioni di dollari per la ricerca sulla sclerosi multipla grazie al programma "Center Without Walls", contribuendo allo sviluppo di terapie approvate dalla FDA come Ocrevus®, Briumvi® e Kesimpta®.
La nomina di Davis è particolarmente significativa mentre Tharimmune avanza con TH104, il loro prodotto sperimentale sviluppato come contromisura contro il fentanyl militarizzato, destinato all'uso militare e ai soccorritori in incidenti chimici, con potenziali applicazioni nella lotta alla crisi degli oppioidi. La sua esperienza con CAN, che si concentra sulla ricerca innovativa per il trattamento delle dipendenze, è in linea con la missione di Tharimmune di sviluppare terapie rivoluzionarie per infiammazione, immunologia e bisogni medici critici ancora insoddisfatti.
Tharimmune (NASDAQ:THAR) ha nombrado a la reconocida filántropa Nancy Davis para su Junta Directiva. Davis, fundadora de Race to Erase MS y Cure Addiction Now (CAN), aporta una amplia experiencia en defensa de pacientes y avance en investigación médica. Su organización Race to Erase MS ha recaudado más de 56 millones de dólares para la investigación de la esclerosis múltiple a través del programa "Center Without Walls", contribuyendo al desarrollo de terapias aprobadas por la FDA como Ocrevus®, Briumvi® y Kesimpta®.
El nombramiento de Davis es especialmente relevante mientras Tharimmune avanza con TH104, su producto en investigación desarrollado como contramedida contra el fentanilo militarizado, destinado para uso militar y para respondedores en incidentes químicos, con aplicaciones potenciales para abordar la crisis de opioides. Su experiencia con CAN, que se enfoca en la investigación innovadora para el tratamiento de adicciones, se alinea con la misión de Tharimmune de desarrollar terapias revolucionarias para inflamación, inmunología y necesidades médicas críticas aún no cubiertas.
Tharimmune (NASDAQ:THAR)는 저명한 자선가 낸시 데이비스를 이사회에 임명했습니다. Race to Erase MS와 Cure Addiction Now (CAN)의 창립자인 데이비스는 환자 옹호 및 의학 연구 발전에 대한 풍부한 경험을 가지고 있습니다. 그녀의 조직인 Race to Erase MS는 'Center Without Walls' 프로그램을 통해 MS 연구를 위해 5,600만 달러 이상을 모금했으며, Ocrevus®, Briumvi®, Kesimpta®와 같은 FDA 승인 치료제 개발에 기여했습니다.
데이비스의 임명은 Tharimmune이 군사용 및 화학 사고 대응자를 위한 무기화 펜타닐 대응책으로 개발 중인 TH104를 진전시키는 가운데 특히 중요합니다. 이 제품은 오피오이드 위기 대응에도 잠재적 응용 가능성이 있습니다. 혁신적인 중독 치료 연구에 중점을 둔 CAN에서의 경험은 염증, 면역학 및 중대한 미충족 의료 수요에 대한 획기적인 치료법 개발이라는 Tharimmune의 사명과 일치합니다.
Tharimmune (NASDAQ:THAR) a nommé la philanthrope renommée Nancy Davis à son conseil d'administration. Davis, fondatrice de Race to Erase MS et Cure Addiction Now (CAN), apporte une vaste expérience dans la défense des patients et l'avancement de la recherche médicale. Son organisation Race to Erase MS a recueilli plus de 56 millions de dollars pour la recherche sur la sclérose en plaques grâce à son programme "Center Without Walls", contribuant au développement de thérapies approuvées par la FDA telles que Ocrevus®, Briumvi® et Kesimpta®.
La nomination de Davis est particulièrement importante alors que Tharimmune fait progresser TH104, leur produit en cours d'investigation développé comme contre-mesure contre le fentanyl militarisé, destiné à un usage militaire et aux intervenants en cas d'incident chimique, avec des applications potentielles pour lutter contre la crise des opioïdes. Son expérience avec CAN, qui se concentre sur la recherche innovante en traitement des addictions, est en accord avec la mission de Tharimmune de développer des thérapies révolutionnaires pour l'inflammation, l'immunologie et les besoins médicaux critiques non satisfaits.
Tharimmune (NASDAQ:THAR) hat die renommierte Philanthropin Nancy Davis in seinen Vorstand berufen. Davis, Gründerin von Race to Erase MS und Cure Addiction Now (CAN), bringt umfangreiche Erfahrung in der Patientenvertretung und der Förderung medizinischer Forschung mit. Ihre Organisation Race to Erase MS hat über 56 Millionen US-Dollar für die MS-Forschung durch das Programm "Center Without Walls" gesammelt und zur Entwicklung von von der FDA zugelassenen Therapien wie Ocrevus®, Briumvi® und Kesimpta® beigetragen.
Die Ernennung von Davis ist besonders bedeutsam, da Tharimmune mit TH104 voranschreitet, ihrem Prüfpräparat, das als Gegenmaßnahme gegen militärisch eingesetzten Fentanyl entwickelt wird und für den Einsatz bei Militär und chemischen Einsatzkräften vorgesehen ist, mit potenziellen Anwendungen zur Bekämpfung der Opioidkrise. Ihre Erfahrung mit CAN, das sich auf innovative Suchterforschung konzentriert, stimmt mit Tharimmunes Mission überein, bahnbrechende Therapien für Entzündungen, Immunologie und kritische ungedeckte medizinische Bedürfnisse zu entwickeln.
- Strategic appointment of Nancy Davis brings valuable experience in medical research advocacy and fundraising
- Potential expansion of TH104 applications from military use to broader opioid crisis solutions
- Access to Davis's extensive network of medical research institutions through 'Center Without Walls' program
- None.
RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today proudly announced the appointment of Nancy Davis, a globally recognized philanthropist, tenacious advocate, and the visionary founder of the renowned Race to Erase MS and Cure Addiction Now foundations, to its Board of Directors. Ms. Davis brings an unparalleled fusion of deep-seated patient advocacy, strategic fundraising, and a profound, personal commitment to accelerating scientific discovery in areas of critical unmet medical need. Her decades of consummate resilience and unwavering patient-centric approach, born from personal experience, make her an ideal and impactful addition to the Board.
Ms. Davis's formidable journey into medical advocacy was ignited by her own diagnosis of multiple sclerosis (MS) in 1991, at the age of 33. Despite being told there was little hope, Nancy refused to accept this prognosis, proactively seeking new therapies and embracing a health-conscious lifestyle. This deeply personal challenge fueled her determination to fundamentally transform the landscape of MS research and treatment. In 1993, she established the Race to Erase MS, an organization that has since raised over
"Tharimmune is incredibly honored and privileged to welcome Nancy Davis to our Board," said Vincent LoPriore, Executive Chairman of the Board of Director. "Nancy's extraordinary dedication to advancing medical research, coupled with her unique and powerful perspective as both a patient advocate and a formidable force for scientific collaboration, is absolutely invaluable as we continue to develop innovative, life-saving therapies. Her vision aligns perfectly with our mission to bring life-changing solutions to patients, especially as we advance our investigational product, TH104. Our lead is being specifically developed to counter the effects of weaponized fentanyl for military use and chemical incident responders, and it may potentially hold significant promise for broader applications in addressing the devastating opioid crisis. Nancy's profound understanding of patient needs and her unwavering commitment to finding solutions for addiction make her an indispensable and critical voice on our Board. Her proven track record of converting personal adversity into global advocacy and tangible scientific progress is truly inspiring."
Ms. Davis co-founded Cure Addiction Now (CAN) with her son, Jason and this pivotal foundation is dedicated to revolutionizing the understanding and treatment of substance use disorder (SUD) by funding cutting-edge, collaborative research that addresses both the physical and emotional aspects of addiction. CAN aims to find therapies that combat withdrawal and cravings, with the ultimate goal of achieving lasting sobriety. Her transformative work with CAN continues to fiercely challenge stigmas and relentlessly push for scientific breakthroughs to combat one of the most pressing public health crises of our time.
"I am thrilled and deeply motivated to join the Board of Directors at Tharimmune and contribute to their ongoing, exciting work," said Nancy Davis. "Throughout my career, I've seen firsthand the profound power of focused, collaborative scientific endeavor to bring about real, tangible change for patients. I am deeply impressed by Tharimmune's commitment to developing critical countermeasures, such as TH104. My personal experiences with the devastating impact of addiction have only strengthened my resolve to support truly innovative solutions and I eagerly look forward to contributing my insights and advocacy to help accelerate the development and potential broader impact of this solution and other transformative therapies."
About Tharimmune, Inc.
Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.
Contacts:
Tharimmune, Inc.
ir@tharimmune.com
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
FAQ
Who is Nancy Davis and why was she appointed to Tharimmune's (NASDAQ:THAR) Board of Directors?
What is Tharimmune's (THAR) lead product TH104 being developed for?
How much funding has Nancy Davis's Race to Erase MS organization raised?
What is the significance of Nancy Davis joining Tharimmune's Board for the company's future?
What major institutions are part of Nancy Davis's 'Center Without Walls' program?
